Delfi Diagnostics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1810 Embarcadero Rd Ste 100, Palo Alto, ...Phone Number
(800) 589-2182Website
www.delfidiagnostics.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Delfi Diagnostics
DELFI Diagnostics specializes in early cancer detection through its innovative Fragmentomics Platform, which utilizes advanced machine learning and next-generation sequencing to analyze cell-free DNA from liquid biopsy samples. Their flagship products include FirstLookLung for both healthcare providers and patients, as well as DELFI-TF for treatment monitoring. The company aims to serve healthcare systems, pharmaceutical partners, and patients by providing scalable and effective cancer screening solutions. With a leadership team comprising experts in genomics, AI, and cancer biology, DELFI is committed to transforming cancer care and improving patient outcomes.Explore more
Delfi Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delfi Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Delfi Diagnostics had a recent Job posting/layoffs
Check out if Delfi Diagnostics is spiking on competitors!
Delfi Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Delfi Diagnostics launches new products
Check if Delfi Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Delfi Diagnostics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Delfi Diagnostics
Earning: See what the market has to say on Delfi Diagnostics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Delfi Diagnostics
Compare insights from companies similar to Delfi Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Delfi Diagnostics
$6.1M
51-200
Private
$325M
2019
DM
David MorgensternVice President, Clinical Development
Company Profile Activity
Activity Insights
Delfi Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Delfi Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Delfi Diagnostics.
Delfi Diagnostics financials insights
Gather financial insights about Delfi Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$100M
2022
Series B
$225M
Delfi Diagnostics Tech Stack
A closer look at the technologies used by Delfi Diagnostics
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Artificial Intelligence
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Events, Medical Research, Healthcare Technology
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Delfi Diagnostics News & Media
DELFI Diagnostics to Present First Clinical Utility Data for Blood-Based Lung Cancer Screening at ATS 2026 International Conference
Late-breaking oral presentation of the L301 FIRSTLUNG Study highlights first-of-its-kind evidence that a blood-based test can increase lung cancer screening uptake; five total presentations span clinical utility, real-world implementation, and health equity across three health systems...DELFI Diagnostics Appoints Charles Newton to Board of Directors
Veteran biotech CFO and former healthcare investment banker joins the DELFI board as the company advances FirstLook Lung toward a pivotal data readout and FDA submission PALO ALTO, Calif., April 27, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative AI-powered...DELFI Diagnostics to Showcase Whole-Genome cfDNA Platform Advances in Cancer Detection and Monitoring at AACR 2026 Annual Meeting
Five poster presentations span lung cancer early detection, immunotherapy response prediction, cancer subtyping, treatment monitoring, and next-generation sequencing platforms PALO ALTO, Calif., April 6, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based...DELFI Diagnostics Appoints Cindy Soriano as Chief Financial Officer and Announces Participation in 44th Annual J.P. Morgan Healthcare Conference
Experienced finance leader to guide company through critical clinical and regulatory milestones; CEO to present at premier healthcare investment event PALO ALTO, Calif., Jan. 8, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Delfi Diagnostics
Sign Up For FreeTo access detailed company insights
DELFI Diagnostics specializes in early cancer detection through its innovative Fragmentomics Platform, which utilizes advanced machine learning and next-generation sequencing to analyze cell-free DNA from liquid biopsy samples. Their flagship products include FirstLookLung for both healthcare providers and patients, as well as DELFI-TF for treatmen... Read More
